Wilson M, Lucas A, Cameron A, Luo M. Budget impact of adding vedolizumab to a health plan formulary as a first-line biologic option for ulcerative colitis and crohn's disease. Am Health Drug Benefits. 2018 Jul;11(5):253-62.
Zhou X, Wang J, Zhang J, Copley-Merriman C, Torigoe Y, Reyes C, Seymour JF, Offner FC, Trneny M, Salles GA. Symptoms and toxicity of rituximab maintenance relative to observation following immunochemotherapy in patients with follicular lymphoma. Hematology. 2015 Apr;129(36). doi: 10.1179/1607845414Y.0000000179
Harris JB, Ward MA, Schwab P. Is response-guided therapy being applied in the clinical setting? The hepatitis C example. Am Health Drug Benefits. 2015 Feb;8(1):22-8.
Patel JC, Taylor SM, Juliao PC, Parobek CM, Janko M, Gonzalez LD, Ortiz L, Padilla N, Tshefu AK, Emch M, Udhayakumar V, Lindblade K, Meshnick SR. Genetic evidence of importation of drug-resistant plasmodium falciparum to Guatemala from the Democratic Republic of the Congo. Emerg Infect Dis. 2014 Jun;20(6):932-40. doi: 10.3201/eid2006.131204
McIntyre LF, Beach WR, Higgins LD, Mordin MM, Mauskopf J, Sweeney CT, Copley-Merriman C. Evidence-based medicine, appropriate-use criteria, and sports medicine: how best to develop meaningful treatment guidelines. Arthroscopy. 2013 Mar 18;29(7):1224-9.
Sacco P, Capkun-Niggli G, Zhang X, Jose R. The economic burden of fragile x syndrome: healthcare resource utilization in the United States. Am Health Drug Benefits. 2013 Mar;6(2):73-83.
Lennert B, Bibeau W, Farrelly E, Sacco P, Schoor T. Assessment of treatment patterns and patient outcomes in levodopa-induced dyskinesias (ASTROID): a US chart review study. Am Health Drug Benefits. 2012 Sep;5(6):347-58.